Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D01048)
Name	Enoxacin
Synonyms	Click to Show/Hide the Synonyms of This API enoxacin; 74011-58-8; Penetrex; Enoxacine; Comprecin; AT-2266; Bactidan; Enoxacino; Enoxacinum; Flumark; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid; Enoxor; Almitil; CI-919; enofloxacin; CI 919; Enoxacin (Penetrex); PD 107779; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; PD-107779; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid; Enoxacin (hydrate); NSC 629661; UNII-325OGW249P; CHEBI:157175; CHEMBL826; 1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; Enoram; Enoxin; 325OGW249P; MFCD00133308; NSC629661; 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-; NSC-629661; AT 2266;CI 919; Enoxacine [French]; Enoxacinum [Latin]; NCGC00016927-01; Enoxacino [Spanish]; Enoksetin; CAS-74011-58-8; DSSTox_CID_2984; 1,8-Naphthyridine-3-carboxylic acid, 1,4-dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-; DSSTox_RID_76818; DSSTox_GSID_22984; Enoxacin sesquihydrate;AT-2266 hydrate;CI-919 hydrate; Enofloxacine; Bactidron; Enoxen; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazinylhydropyridino[2,3-b]pyridine-3-carboxylic acid; Penetrex (TN); SMR000058233; CCRIS 5242; Enoxacin (USAN/INN); SR-01000000202; NSC 627409; BRN 3628995; Enoxacin [USAN:INN:BAN:JAN]; ENX; Prestwick_708; Spectrum_001539; Prestwick0_000353; Prestwick1_000353; Prestwick2_000353; Prestwick3_000353; Spectrum2_001731; Spectrum3_001570; Spectrum4_000166; Spectrum5_001044; E0762; Epitope ID:119069; Oprea1_147866; SCHEMBL33963; BSPBio_000445; BSPBio_003080; Enoxacin, analytical standard; KBioGR_000651; KBioSS_002019; MLS000069645; MLS006011976; BIDD:GT0191; DivK1c_000420; SPECTRUM1503215; SPBio_001802; SPBio_002366; BPBio1_000491; GTPL8882; DTXSID5022984; BCBcMAP01_000009; HMS501E22; KBio1_000420; KBio2_002019; KBio2_004587; KBio2_007155; KBio3_002580; NINDS_000420; HMS1569G07; HMS1922I17; HMS2090E10; HMS2092N20; HMS2233K20; HMS3372A12; HMS3655M08; HMS3715H13; Pharmakon1600-01503215; BCP22623; HY-B0268; Tox21_110688; BDBM50296358; CCG-39452; NSC758416; s1756; ZINC19594549; AKOS015838626; Tox21_110688_1; DB00467; KS-5190; MCULE-2632820619; NE58656; NSC-758416; IDI1_000420; SMP1_000113; NCGC00016927-02; NCGC00016927-03; NCGC00016927-04; NCGC00016927-05; NCGC00016927-06; NCGC00016927-07; NCGC00016927-08; NCGC00016927-10; NCGC00016927-11; NCGC00023864-03; NCGC00023864-04; NCGC00178309-01; NCGC00178309-02; K259; NCI60_009618; ST044514; SBI-0051788.P002; AB0014125; DB-055829; FT-0630825; SW196857-3; C06979; D00310; J10280; 1, 6-fluoro-1,4-dihydro- 4-oxo-7-piperazinyl; AB00052328-09; AB00052328_10; AB00052328_11; 011E588; A837996; Q1639616; SR-01000000202-2; SR-01000000202-3; BRD-K78113049-001-05-5; BRD-K78113049-001-07-1; BRD-K78113049-001-12-1; Z1551429746; 84294-96-2 (.1.5H2O); 1-ethyl-6-fluoranyl-4-oxidanylidene-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid
Clinical Status	Approved
PubChem CID	3229
Formula	C15H17FN4O3
Canonical SMILES	CCN1C=C(C(=O)C2=CC(=C(N=C21)N3CCNCC3)F)C(=O)O
InChI	1S/C15H17FN4O3/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20/h7-8,17H,2-6H2,1H3,(H,22,23)
InChIKey	IDYZIJYBMGIQMJ-UHFFFAOYSA-N
	Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure	<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=3229"></iframe>
Structure	3D MOL		2D MOL
Physicochemical Properties	Molecular Weight	320.32	Topological Polar Surface Area	85.8
	XlogP	-0.2	Complexity	521
	Heavy Atom Count	23	Rotatable Bond Count	3
	Hydrogen Bond Donor Count	2	Hydrogen Bond Acceptor Count	8

Full List of Drug Formulations (DFMs) Containing This API
Enoxacin 1% cream			Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s)
Drug Formulation 1	DFM Info click to show the detail info of this DFM
All DIGs	Click to Show/Hide the Full List of DIGs in This DFM Benzoic Acid; Octyldodecanol; Peglicol 5 Oleate; Pegoxol 7 Stearate; Propylene Glycol; Purified Water; Stearyl Alcohol
Dosage Form	Cream
Company	Biofrontera ; Cutanea Life Sciences
DIG(s) with Biological Activity
	DIG Name	DIG Info	Representative Biological Activity of This DIG	REF
	Benzoic acid	DIG Info	FHA-HIT-interacting protein (Ki = 1.9 nM)	[1]
	Propylene glycol	DIG Info	Albendazole monooxygenase (Inhibition ratio < 20 %)	[2]

References
1	WO patent application no. 2017162840A1, SENSITIZATION OF CANCER CELLS TO NAMPT INHIBITORS BY NICOTINIC ACID PHOSPHORIBOSYLTRANSFERASE NEUTRALIZATION.
2	Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.